Clinical trial

TH1902 in Patients With Advanced Solid Tumors

NCT04706962

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-03-04

PhasePHASE1

Study timeline

Study start (actual)2021-03-04Date precision: day

Registry last updated2025-04-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Solid Tumorunresolved

TNBC - Triple-Negative Breast Cancerunresolved

Hormone Receptor-positive Breast Cancerverified · MONDO: hormone receptor-positive breast cancer

Epithelial Ovarian Cancerverified · MONDO: ovarian carcinoma

Endometrial Cancerverified · MONDO: endometrial cancer

Cutaneous Melanomaverified · MONDO: cutaneous melanoma

Thyroid Cancerverified · MONDO: thyroid cancer

Small-cell Lung Cancercandidate · MONDO: small cell lung carcinoma

Prostate Cancerverified · MONDO: prostate cancer

SORT1+ Cancersunresolved

Interventions

Sponsors & collaborators

Theratechnologieslead sponsor

PPD Development, LPcollaborator

Altasciences Company Inc.collaborator

Windtree Therapeuticscollaborator

Syneos Healthcollaborator

Innovaderm Research Inc.collaborator

Mapped research locations

HoustonTexas, United States1 DallasTexas, United States1 MontrealQuebec, Canada1 DetroitMichigan, United States1 Grand RapidsMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04706962 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.